<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37728652</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1613-7671</ISSN><JournalIssue CitedMedium="Internet"><Volume>135</Volume><Issue>Suppl 5</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Wiener klinische Wochenschrift</Title><ISOAbbreviation>Wien Klin Wochenschr</ISOAbbreviation></Journal><ArticleTitle>[Diagnostic and therapy of lupus nephritis&#xa0;- 2023].</ArticleTitle><Pagination><StartPage>675</StartPage><EndPage>687</EndPage><MedlinePgn>675-687</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00508-023-02263-8</ELocationID><Abstract><AbstractText>The manuscript summarizes the consensus of the Austrian Society of Nephrology on the diagnosis and therapy of lupusnephritis, which is built on existing studies and literature. We discuss in detail the immunosuppressive treatment in proliferative forms of lupusnephritis (III&#xa0;and&#xa0;IV&#x202f;&#xb1;&#x2009;V) and in pure lupusnephritis&#xa0;V with nephrotic-range proteinuria. Furthermore, the supportive medication in lupusnephritis is summarized in the consensus. The figures were designed to provide the reader a&#xa0;guidance through the therapeutical approach in lupusnephritis for the daily practice.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Odler</LastName><ForeName>Balazs</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Abteilung f&#xfc;r Nephrologie, Innere Medizin, Medizinische Universit&#xe4;t Graz, Graz, &#xd6;sterreich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollheimer</LastName><ForeName>Marion J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Institut f&#xfc;r Pathologie, Medizinische Universit&#xe4;t Graz, Graz, &#xd6;sterreich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kronbichler</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department Innere Medizin 4 (Nephrologie und Hypertensiologie), Medizinische Universit&#xe4;t Innsbruck, Innsbruck, &#xd6;sterreich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe4;emann</LastName><ForeName>Marcus D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>6. Medizinische Abteilung mit Nephrologie &amp; Dialyse, Klinik Ottakring, Wien, &#xd6;sterreich.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medizinische Fakult&#xe4;t, SFU, Wien, &#xd6;sterreich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Windpessl</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Abteilung f&#xfc;r Innere Medizin IV, Klinikum Wels-Grieskirchen, Wels, &#xd6;sterreich.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medizinische Fakult&#xe4;t, JKU, Linz, &#xd6;sterreich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauckler</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department Innere Medizin 4 (Nephrologie und Hypertensiologie), Medizinische Universit&#xe4;t Innsbruck, Innsbruck, &#xd6;sterreich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudnicki</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department Innere Medizin 4 (Nephrologie und Hypertensiologie), Medizinische Universit&#xe4;t Innsbruck, Innsbruck, &#xd6;sterreich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zitt</LastName><ForeName>Emanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Abteilung f&#xfc;r Innere Medizin III (Nephrologie, Dialyse und Hypertensiologie), Akademisches Lehrkrankenhaus Feldkirch, Feldkirch, &#xd6;sterreich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Irmgard</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Vasculitis.at, Wien, &#xd6;sterreich.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunologiezentrum Z&#xfc;rich (IZZ), Z&#xfc;rich, Schweiz.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lhotta</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Abteilung f&#xfc;r Innere Medizin III (Nephrologie, Dialyse und Hypertensiologie), Akademisches Lehrkrankenhaus Feldkirch, Feldkirch, &#xd6;sterreich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eller</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Abteilung f&#xfc;r Nephrologie, Innere Medizin, Medizinische Universit&#xe4;t Graz, Graz, &#xd6;sterreich. kathrin.eller@medunigraz.at.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Diagnostik und Therapie der Lupusnephritis&#xa0;&#x2013; 2023.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>Wien Klin Wochenschr</MedlineTA><NlmUniqueID>21620870R</NlmUniqueID><ISSNLinking>0043-5325</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001317" MajorTopicYN="N" Type="Geographic">Austria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009398" MajorTopicYN="Y">Nephrology</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText>Das vorliegende Manuskript fasst die Empfehlungen der &#xd6;sterreichischen Gesellschaft f&#xfc;r Nephrologie zur Diagnose und Therapie der Lupusnephritis zusammen und erl&#xe4;utert die Hintergr&#xfc;nde der entsprechenden Empfehlungen anhand der vorhandenen Literatur. Wir besprechen im Detail die immunsuppressive Therapie in proliferativen Stadien der Lupusnephritis (Stadium&#xa0;III und&#xa0;IV mit/ohne Stadium&#xa0;V) und in der Lupusnephritis im reinen Stadium&#xa0;V mit gro&#xdf;er Proteinurie. Zudem wird auch die konservative, supportive Therapie der Lupusnephritis detailliert besprochen. In den Abbildungen haben wir versucht, einen Leitfaden f&#xfc;r die Praxis zur Therapie der Lupusnephritis zu erstellen.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Immunosuppression</Keyword><Keyword MajorTopicYN="N">Proliferative lupus nephritis</Keyword><Keyword MajorTopicYN="N">Proteinuria</Keyword><Keyword MajorTopicYN="N">Supportive therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>20</Day><Hour>12</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>20</Day><Hour>11</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37728652</ArticleId><ArticleId IdType="pmc">PMC10511585</ArticleId><ArticleId IdType="doi">10.1007/s00508-023-02263-8</ArticleId><ArticleId IdType="pii">10.1007/s00508-023-02263-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825&#x2013;835. doi: 10.2215/CJN.05780616.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.05780616</ArticleId><ArticleId IdType="pmc">PMC5477208</ArticleId><ArticleId IdType="pubmed">27821390</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis. 2020;76(2):265&#x2013;281. doi: 10.1053/j.ajkd.2019.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2019.10.017</ArticleId><ArticleId IdType="pubmed">32220510</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400&#x2013;1412. doi: 10.1002/art.40930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannico G, Fogo AB. Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis? Clin J Am Soc Nephrol. 2013;8(1):138&#x2013;145. doi: 10.2215/CJN.03400412.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.03400412</ArticleId><ArticleId IdType="pubmed">22977215</ArticleId></ArticleIdList></Reference><Reference><Citation>Corwin HL, Schwartz MM, Lewis EJ. The importance of sample size in the interpretation of the renal biopsy. Am J Nephrol. 1988;8(2):85&#x2013;89. doi: 10.1159/000167563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000167563</ArticleId><ArticleId IdType="pubmed">3394725</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening JJ, D&#x2019;Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15(2):241&#x2013;250. doi: 10.1097/01.ASN.0000108969.21691.5D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ASN.0000108969.21691.5D</ArticleId><ArticleId IdType="pubmed">14747370</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera GA, Russell WJ, Isaac J, Turbat-Herrera EA, Tagouri YM, Sanders PW, et al. Glomerulopathic light chain-mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangiopathic findings documented in vivo. Ultrastruct Pathol. 1999;23(2):107&#x2013;126. doi: 10.1080/019131299281752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/019131299281752</ArticleId><ArticleId IdType="pubmed">10369104</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789&#x2013;796. doi: 10.1016/j.kint.2017.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.11.023</ArticleId><ArticleId IdType="pubmed">29459092</ArticleId></ArticleIdList></Reference><Reference><Citation>Umeda R, Ogata S, Hara S, Takahashi K, Inaguma D, Hasegawa M, et al. Comparison of the 2018 and 2003 International Society of Nephrology/Renal Pathology Society classification in terms of renal prognosis in patients of lupus nephritis: a&#xa0;retrospective cohort study. Arthritis Res Ther. 2020;22(1):260. doi: 10.1186/s13075-020-02358-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-020-02358-x</ArticleId><ArticleId IdType="pmc">PMC7640657</ArticleId><ArticleId IdType="pubmed">33148339</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin HA, 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 1984;25(4):689&#x2013;695. doi: 10.1038/ki.1984.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1984.75</ArticleId><ArticleId IdType="pubmed">6482173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz Irastorza G, Espinosa G, Frutos MA, Jimenez Alonso J, Praga M, Pallares L, et al. Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.) Nefrologia. 2012;32(Suppl 1):1&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">22293933</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1&#x2013;S276.</Citation><ArticleIdList><ArticleId IdType="pubmed">34556256</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713&#x2013;723. doi: 10.1136/annrheumdis-2020-216924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId><ArticleId IdType="pubmed">32220834</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012;64(6):797&#x2013;808. doi: 10.1002/acr.21664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21664</ArticleId><ArticleId IdType="pmc">PMC3437757</ArticleId><ArticleId IdType="pubmed">22556106</ArticleId></ArticleIdList></Reference><Reference><Citation>van Tellingen A, Voskuyl AE, Vervloet MG, Bijl M, de Sevaux RG, Berger SP, et al. Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis. Neth J Med. 2012;70(4):199&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">22641632</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7. doi: 10.1038/s41572-019-0141-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0141-9</ArticleId><ArticleId IdType="pubmed">31974366</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall&#x2019;Era M, Cisternas MG, Smilek DE, Straub L, Houssiau FA, Cervera R, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015;67(5):1305&#x2013;1313. doi: 10.1002/art.39026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39026</ArticleId><ArticleId IdType="pubmed">25605554</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamirou F, D&#x2019;Cruz D, Sangle S, Remy P, Vasconcelos C, Fiehn C, et al. Long-term follow-up of the MAINTAIN Nephritis trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2016;75(3):526&#x2013;531. doi: 10.1136/annrheumdis-2014-206897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206897</ArticleId><ArticleId IdType="pmc">PMC4789692</ArticleId><ArticleId IdType="pubmed">25757867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostopoulou M, Fanouriakis A, Cheema K, Boletis J, Bertsias G, Jayne D, et al. Management of lupus nephritis: a&#xa0;systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. RMD Open. 2020;6:2. doi: 10.1136/rmdopen-2020-001263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001263</ArticleId><ArticleId IdType="pmc">PMC7425195</ArticleId><ArticleId IdType="pubmed">32699043</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugolini-Lopes MR, Seguro LPC, Castro MXF, Daffre D, Lopes AC, Borba EF, et al. Early proteinuria response: a&#xa0;valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? Lupus Sci Med. 2017;4(1):e000213. doi: 10.1136/lupus-2017-000213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2017-000213</ArticleId><ArticleId IdType="pmc">PMC5724342</ArticleId><ArticleId IdType="pubmed">29238603</ArticleId></ArticleIdList></Reference><Reference><Citation>Collado MV, Dorado E, Rausch S, Gomez G, Khoury M, Zazzetti F, et al. Long-term outcome of lupus nephritis class II in Argentine patients: an open retrospective analysis. J Clin Rheumatol. 2016;22(6):299&#x2013;306. doi: 10.1097/RHU.0000000000000395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000000395</ArticleId><ArticleId IdType="pmc">PMC4998123</ArticleId><ArticleId IdType="pubmed">27152693</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung WA, Su J, Touma Z. Predictors of good long-term renal outcomes in lupus nephritis: results from a&#xa0;single lupus cohort. Biomed Res Int. 2017;2017:5312960. doi: 10.1155/2017/5312960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/5312960</ArticleId><ArticleId IdType="pmc">PMC5585546</ArticleId><ArticleId IdType="pubmed">28904963</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay M, Dall&#x2019;Era M, Fishbein J, Kalunian K, Lesser M, Sanchez-Guerrero J, et al. Establishing surrogate kidney end points for lupus nephritis clinical trials: development and validation of a&#xa0;novel approach to predict future kidney outcomes. Arthritis Rheumatol. 2019;71(3):411&#x2013;419. doi: 10.1002/art.40724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40724</ArticleId><ArticleId IdType="pubmed">30225865</ArticleId></ArticleIdList></Reference><Reference><Citation>Malvar A, Pirruccio P, Alberton V, Lococo B, Recalde C, Fazini B, et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant. 2017;32(8):1338&#x2013;1344. doi: 10.1093/ndt/gfv296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfv296</ArticleId><ArticleId IdType="pmc">PMC5837387</ArticleId><ArticleId IdType="pubmed">26250434</ArticleId></ArticleIdList></Reference><Reference><Citation>Zickert A, Sundelin B, Svenungsson E, Gunnarsson I. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med. 2014;1(1):e000018. doi: 10.1136/lupus-2014-000018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2014-000018</ArticleId><ArticleId IdType="pmc">PMC4213828</ArticleId><ArticleId IdType="pubmed">25379188</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamirou F, Lauwerys BR, Dall&#x2019;Era M, Mackay M, Rovin B, Cervera R, et al. A&#xa0;proteinuria cut-off level of 0.7&#x202f;g/day after 12&#xa0;months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med. 2015;2(1):e000123. doi: 10.1136/lupus-2015-000123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2015-000123</ArticleId><ArticleId IdType="pmc">PMC4654096</ArticleId><ArticleId IdType="pubmed">26629352</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodis I, Adamichou C, Aydin S, Gomez A, Demoulin N, Weinmann-Menke J, et al. Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Rheumatology (Oxford) 2020;59(11):3424&#x2013;3434. doi: 10.1093/rheumatology/keaa129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa129</ArticleId><ArticleId IdType="pubmed">32353879</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodis I, Tamirou F, Houssiau FA. Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med. 2020;7(1):e000389. doi: 10.1136/lupus-2020-000389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000389</ArticleId><ArticleId IdType="pmc">PMC7046967</ArticleId><ArticleId IdType="pubmed">32153796</ArticleId></ArticleIdList></Reference><Reference><Citation>Touma Z, Urowitz MB, Ibanez D, Gladman DD. Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. J Rheumatol. 2014;41(4):688&#x2013;697. doi: 10.3899/jrheum.130005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.130005</ArticleId><ArticleId IdType="pubmed">24429170</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78[6:736&#x2013;745. doi: 10.1136/annrheumdis-2019-215089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha C, Alexander S, Ashby D, Lee J, Chusney G, Cairns TD, et al. Hydroxycloroquine blood concentration in lupus nephritis: a&#xa0;determinant of disease outcome? Nephrol Dial Transplant. 2018;33(9):1604&#x2013;1610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7170714</ArticleId><ArticleId IdType="pubmed">29186572</ArticleId></ArticleIdList></Reference><Reference><Citation>Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453&#x2013;1460. doi: 10.1001/jamaophthalmol.2014.3459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2014.3459</ArticleId><ArticleId IdType="pubmed">25275721</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Loutan J, Bruchfeld A, Juarez GMF, Floege J, Goumenos D, et al. The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO. Nephrol Dial Transplant. 2021 doi: 10.1093/ndt/gfab351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfab351</ArticleId><ArticleId IdType="pubmed">34888694</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):753&#x2013;779. doi: 10.1016/j.kint.2021.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.015</ArticleId><ArticleId IdType="pubmed">34556300</ArticleId></ArticleIdList></Reference><Reference><Citation>Farinha F, Pepper RJ, Oliveira DG, McDonnell T, Isenberg DA, Rahman A. Outcomes of membranous and proliferative lupus nephritis&#x2014;analysis of a&#xa0;single-centre cohort with more than 30&#xa0;years of follow-up. Rheumatology (Oxford) 2020;59(11):3314&#x2013;3323. doi: 10.1093/rheumatology/keaa103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa103</ArticleId><ArticleId IdType="pmc">PMC7590413</ArticleId><ArticleId IdType="pubmed">32303057</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun HO, Hu WX, Xie HL, Zhang HT, Chen HP, Zeng CH, et al. Long-term outcome of Chinese patients with membranous lupus nephropathy. Lupus. 2008;17(1):56&#x2013;61. doi: 10.1177/0961203307083443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203307083443</ArticleId><ArticleId IdType="pubmed">18089685</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin HA, 3rd, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol. 2009;20(4):901&#x2013;911. doi: 10.1681/ASN.2008060665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2008060665</ArticleId><ArticleId IdType="pmc">PMC2663831</ArticleId><ArticleId IdType="pubmed">19297556</ArticleId></ArticleIdList></Reference><Reference><Citation>Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77(2):152&#x2013;160. doi: 10.1038/ki.2009.412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2009.412</ArticleId><ArticleId IdType="pubmed">19890271</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavarot N, Verhelst D, Pardon A, Caudwell V, Mercadal L, Sacchi A, et al. Rituximab alone as induction therapy for membranous lupus nephritis: A&#xa0;multicenter retrospective study. Medicine (Baltimore) 2017;96(27):e7429. doi: 10.1097/MD.0000000000007429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000007429</ArticleId><ArticleId IdType="pmc">PMC5502178</ArticleId><ArticleId IdType="pubmed">28682905</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Tang X, Liu Q, Chen W, Fu P, Liu F, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A&#xa0;multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235&#x2013;244. doi: 10.1053/j.ajkd.2010.08.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2010.08.036</ArticleId><ArticleId IdType="pubmed">21177013</ArticleId></ArticleIdList></Reference><Reference><Citation>Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72(8):1280&#x2013;1286. doi: 10.1136/annrheumdis-2012-202844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202844</ArticleId><ArticleId IdType="pubmed">23740227</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap DY, Yu X, Chen XM, Lu F, Chen N, Li XW, et al. Pilot 24&#xa0;month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton) 2012;17(4):352&#x2013;357. doi: 10.1111/j.1440-1797.2012.01574.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1797.2012.01574.x</ArticleId><ArticleId IdType="pubmed">22295934</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Rovin B. A&#xa0;pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int. 2016;90(3):493&#x2013;501. doi: 10.1016/j.kint.2016.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2016.05.017</ArticleId><ArticleId IdType="pubmed">27378475</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Rovin BH. Current and emerging therapies for lupus nephritis. J Am Soc Nephrol. 2016;27(10):2929&#x2013;2939. doi: 10.1681/ASN.2016040415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2016040415</ArticleId><ArticleId IdType="pmc">PMC5042683</ArticleId><ArticleId IdType="pubmed">27283496</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a&#xa0;randomized trial. Ann Intern Med. 2015;162(1):18&#x2013;26. doi: 10.7326/M14-1030.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-1030</ArticleId><ArticleId IdType="pubmed">25383558</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a&#xa0;double-blind, randomised, multicentre, placebo-controlled, phase&#xa0;3&#xa0;trial. Lancet. 2021;397(10289):2070&#x2013;2080. doi: 10.1016/S0140-6736(21)00578-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00578-X</ArticleId><ArticleId IdType="pubmed">33971155</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117&#x2013;1128. doi: 10.1056/NEJMoa2001180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodis I, Stockfelt M, Sjowall C. B cell therapy in systemic lupus erythematosus: from rationale to clinical practice. Front Med (Lausanne) 2020;7:316. doi: 10.3389/fmed.2020.00316.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00316</ArticleId><ArticleId IdType="pmc">PMC7381321</ArticleId><ArticleId IdType="pubmed">32754605</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222&#x2013;233. doi: 10.1002/art.27233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27233</ArticleId><ArticleId IdType="pmc">PMC4548300</ArticleId><ArticleId IdType="pubmed">20039413</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215&#x2013;1226. doi: 10.1002/art.34359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34359</ArticleId><ArticleId IdType="pubmed">22231479</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall&#x2019;Era M, et al. Peripheral blood B cell depletion after Rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502&#x2013;1509. doi: 10.2215/CJN.01070118.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.01070118</ArticleId><ArticleId IdType="pmc">PMC6218830</ArticleId><ArticleId IdType="pubmed">30089664</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a&#xa0;randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100&#x2013;107. doi: 10.1136/annrheumdis-2021-220920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220920</ArticleId><ArticleId IdType="pmc">PMC8762029</ArticleId><ArticleId IdType="pubmed">34615636</ArticleId></ArticleIdList></Reference><Reference><Citation>Jourde-Chiche N, Costedoat-Chalumeau N, Baumstarck K, Loundou A, Bouillet L, Burtey S, et al. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a&#xa0;multicentre randomised controlled trial. Ann Rheum Dis. 2022;81(10):1420&#x2013;1427. doi: 10.1136/annrheumdis-2022-222435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-222435</ArticleId><ArticleId IdType="pmc">PMC9484365</ArticleId><ArticleId IdType="pubmed">35725295</ArticleId></ArticleIdList></Reference><Reference><Citation>Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, et al. The actin cytoskeleton of kidney podocytes is a&#xa0;direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931&#x2013;938. doi: 10.1038/nm.1857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1857</ArticleId><ArticleId IdType="pmc">PMC4109287</ArticleId><ArticleId IdType="pubmed">18724379</ArticleId></ArticleIdList></Reference><Reference><Citation>Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75(6):952&#x2013;957. doi: 10.1136/annrheumdis-2015-208916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-208916</ArticleId><ArticleId IdType="pubmed">26933146</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepper R, Griffith M, Kirwan C, Levy J, Taube D, Pusey C, et al. Rituximab is an effective treatment for lupus nephritis and allows a&#xa0;reduction in maintenance steroids. Nephrol Dial Transplant. 2009;24(12):3717&#x2013;3723. doi: 10.1093/ndt/gfp336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfp336</ArticleId><ArticleId IdType="pubmed">19617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Roccatello D, Sciascia S, Baldovino S, Rossi D, Alpa M, Naretto C, et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment. Autoimmun Rev. 2015;14(12):1123&#x2013;1130. doi: 10.1016/j.autrev.2015.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2015.07.017</ArticleId><ArticleId IdType="pubmed">26244817</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronbichler A, Brezina B, Gauckler P, Quintana LF, Jayne DRW. Refractory lupus nephritis: When, why and how to treat. Autoimmun Rev. 2019;18(5):510&#x2013;518. doi: 10.1016/j.autrev.2019.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2019.03.004</ArticleId><ArticleId IdType="pubmed">30844548</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora S, Rovin BH. Expert perspective: an approach to refractory lupus nephritis. Arthritis Rheumatol. 2022;74(6):915&#x2013;926. doi: 10.1002/art.42092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42092</ArticleId><ArticleId IdType="pmc">PMC9156543</ArticleId><ArticleId IdType="pubmed">35166048</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W, Farinha F, Isenberg DA, Rahman A. Survival analysis of mortality and development of lupus nephritis in patients with systemic lupus erythematosus up to 40-years of follow-up. Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac218</ArticleId><ArticleId IdType="pmc">PMC9788815</ArticleId><ArticleId IdType="pubmed">35412595</ArticleId></ArticleIdList></Reference><Reference><Citation>Tselios K, Gladman DD, Sheane BJ, Su J, Urowitz M. All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43&#xa0;years (1971&#x2013;2013) Ann Rheum Dis. 2019;78(6):802&#x2013;806. doi: 10.1136/annrheumdis-2018-214802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214802</ArticleId><ArticleId IdType="pubmed">30992296</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap DY, Tang CS, Ma MK, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. 2012;27(8):3248&#x2013;3254. doi: 10.1093/ndt/gfs073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfs073</ArticleId><ArticleId IdType="pubmed">22523116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheigh JS, Kim H, Stenzel KH, Tapia L, Sullivan JF, Stubenbord W, et al. Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. Am J Kidney Dis. 1990;16(3):189&#x2013;195. doi: 10.1016/S0272-6386(12)81017-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0272-6386(12)81017-1</ArticleId><ArticleId IdType="pubmed">2399912</ArticleId></ArticleIdList></Reference><Reference><Citation>Derner O, Kramer A, Hruskova Z, Arici M, Collart F, Finne P, et al. Incidence of kidney replacement therapy and subsequent outcomes among patients with systemic lupus erythematosus: findings from the ERA registry. Am J Kidney Dis. 2022;79(5):635&#x2013;645. doi: 10.1053/j.ajkd.2021.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2021.09.016</ArticleId><ArticleId IdType="pubmed">34752912</ArticleId></ArticleIdList></Reference><Reference><Citation>Rietveld A, Berden JH. Renal replacement therapy in lupus nephritis. Nephrol Dial Transplant. 2008;23(10):3056&#x2013;3060. doi: 10.1093/ndt/gfn429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfn429</ArticleId><ArticleId IdType="pubmed">18662976</ArticleId></ArticleIdList></Reference><Reference><Citation>Swai J, Zhao X, Noube JR, Ming G. Systematic review and meta-analysis of clinical outcomes comparison between different initial dialysis modalities in end-stage renal disease patients due to lupus nephritis prior to renal transplantation. BMC Nephrol. 2020;21(1):156. doi: 10.1186/s12882-020-01811-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-020-01811-y</ArticleId><ArticleId IdType="pmc">PMC7195760</ArticleId><ArticleId IdType="pubmed">32357924</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattos P, Santiago MB. Disease activity in systemic lupus erythematosus patients with end-stage renal disease: systematic review of the literature. Clin Rheumatol. 2012;31(6):897&#x2013;905. doi: 10.1007/s10067-012-1957-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-012-1957-9</ArticleId><ArticleId IdType="pubmed">22415467</ArticleId></ArticleIdList></Reference><Reference><Citation>Krane NK, Burjak K, Archie M, O&#x2019;Donovan R. Persistent lupus activity in end-stage renal disease. Am J Kidney Dis. 1999;33(5):872&#x2013;879. doi: 10.1016/S0272-6386(99)70419-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0272-6386(99)70419-1</ArticleId><ArticleId IdType="pubmed">10213642</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap KS, Urowitz MB, Mahood Q, Medina-Rosas J, Sabapathy A, Lawson D, et al. The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort. Semin Arthritis Rheum. 2017;46(6):791&#x2013;797. doi: 10.1016/j.semarthrit.2016.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2016.09.008</ArticleId><ArticleId IdType="pubmed">27769590</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark WF, Jevnikar AM. Renal transplantation for end-stage renal disease caused by systemic lupus erythematosus nephritis. Semin Nephrol. 1999;19(1):77&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">9952283</ArticleId></ArticleIdList></Reference><Reference><Citation>Goral S, Ynares C, Shappell SB, Snyder S, Feurer ID, Kazancioglu R, et al. Recurrent lupus nephritis in renal transplant recipients revisited: it is not rare. Transplantation. 2003;75(5):651&#x2013;656. doi: 10.1097/01.TP.0000053750.59630.83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.TP.0000053750.59630.83</ArticleId><ArticleId IdType="pubmed">12640304</ArticleId></ArticleIdList></Reference><Reference><Citation>Dao KH, Bermas BL. Systemic lupus erythematosus management in pregnancy. Int J Womens Health. 2022;14:199&#x2013;211. doi: 10.2147/IJWH.S282604.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJWH.S282604</ArticleId><ArticleId IdType="pmc">PMC8859727</ArticleId><ArticleId IdType="pubmed">35210867</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>